Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefan Willmann

Showing results (41-50 of 80) with videos related to

Pageof 8
Sort By:
Journal of Clinical Pharmacology|November 9, 2023
The Importance of Assessing Drug Pharmacokinetics and Pharmacodynamics in the Obese Population During Drug DevelopmentKenneth T Moore, Peter N Zannikos, Joanna C Masters, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 17, 2019
Application of Physiologically-Based and Population Pharmacokinetic Modeling for Dose Finding and Confirmation During the Pediatric Development of MoxifloxacinStefan Willmann, Matthias Frei, Gabriele Sutter, et al.
Journal of Pharmacokinetics and Pharmacodynamics|April 14, 2007
Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugsStefan Willmann, Karsten Höhn, Andrea Edginton, et al.
Journal of Clinical Pharmacology|November 18, 2020
Applications of Physiologically Based Pharmacokinetic Modeling of Rivaroxaban-Renal and Hepatic Impairment and Drug-Drug Interaction PotentialStefan Willmann, Katrin Coboeken, Stefanie Kapsa, et al.
Journal of Clinical Pharmacology|April 23, 2022
Population Pharmacokinetics of Nifurtimox in Adult and Pediatric Patients With Chagas DiseaseIbrahim Ince, Klaas Prins, Stefan Willmann, et al.
Clinical Pharmacokinetics|May 9, 2018
A Physiologically-Based Pharmacokinetic Model to Describe Ciprofloxacin Pharmacokinetics Over the Entire Span of LifeJan-Frederik Schlender, Donato Teutonico, Katrin Coboeken, et al.
Journal of Pharmacokinetics and Pharmacodynamics|December 14, 2017
A generic whole body physiologically based pharmacokinetic model for therapeutic proteins in PK-SimChristoph Niederalt, Lars Kuepfer, Juri Solodenko, et al.
In Silico Pharmacology|December 16, 2014
Using Bayesian-PBPK modeling for assessment of inter-individual variability and subgroup stratificationMarkus Krauss, Rolf Burghaus, Jörg Lippert, et al.
Journal of Clinical Pharmacology|September 11, 2019
Predictive Pediatric Modeling and Simulation Using Ontogeny InformationIbrahim Ince, Juri Solodenko, Sebastian Frechen, et al.
CPT: Pharmacometrics & Systems Pharmacology|April 17, 2018
Integrated Population Pharmacokinetic Analysis of Rivaroxaban Across Multiple Patient PopulationsStefan Willmann, Liping Zhang, Matthias Frede, et al.
Pageof 8

Showing results (41-50 of 80) with videos related to

Sort By:
Pageof 8
Journal of Clinical Pharmacology|November 9, 2023
The Importance of Assessing Drug Pharmacokinetics and Pharmacodynamics in the Obese Population During Drug DevelopmentKenneth T Moore, Peter N Zannikos, Joanna C Masters, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 17, 2019
Application of Physiologically-Based and Population Pharmacokinetic Modeling for Dose Finding and Confirmation During the Pediatric Development of MoxifloxacinStefan Willmann, Matthias Frei, Gabriele Sutter, et al.
Journal of Pharmacokinetics and Pharmacodynamics|April 14, 2007
Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugsStefan Willmann, Karsten Höhn, Andrea Edginton, et al.
Journal of Clinical Pharmacology|November 18, 2020
Applications of Physiologically Based Pharmacokinetic Modeling of Rivaroxaban-Renal and Hepatic Impairment and Drug-Drug Interaction PotentialStefan Willmann, Katrin Coboeken, Stefanie Kapsa, et al.
Journal of Clinical Pharmacology|April 23, 2022
Population Pharmacokinetics of Nifurtimox in Adult and Pediatric Patients With Chagas DiseaseIbrahim Ince, Klaas Prins, Stefan Willmann, et al.
Clinical Pharmacokinetics|May 9, 2018
A Physiologically-Based Pharmacokinetic Model to Describe Ciprofloxacin Pharmacokinetics Over the Entire Span of LifeJan-Frederik Schlender, Donato Teutonico, Katrin Coboeken, et al.
Journal of Pharmacokinetics and Pharmacodynamics|December 14, 2017
A generic whole body physiologically based pharmacokinetic model for therapeutic proteins in PK-SimChristoph Niederalt, Lars Kuepfer, Juri Solodenko, et al.
In Silico Pharmacology|December 16, 2014
Using Bayesian-PBPK modeling for assessment of inter-individual variability and subgroup stratificationMarkus Krauss, Rolf Burghaus, Jörg Lippert, et al.
Journal of Clinical Pharmacology|September 11, 2019
Predictive Pediatric Modeling and Simulation Using Ontogeny InformationIbrahim Ince, Juri Solodenko, Sebastian Frechen, et al.
CPT: Pharmacometrics & Systems Pharmacology|April 17, 2018
Integrated Population Pharmacokinetic Analysis of Rivaroxaban Across Multiple Patient PopulationsStefan Willmann, Liping Zhang, Matthias Frede, et al.
Pageof 8